Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00051168 · ClinicalTrials.gov registry record · Phase 3
A Long-term Safety Study of Once-daily Travatan
A Phase 3 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 502
- Enrollment target
NCT00051168: Completed Phase 3 study, sponsored by Alcon Research.
NCT00051168 is a Phase 3 study that has completed, run by Alcon Research. The registered enrollment target is 502 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00051168, a Phase 3 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 502 participants
- Enrollment target
Study Summary
Long term safety study of TRAVATAN in patients with Open-angle glaucoma or ocular hypertension.
Primary Outcome
Mean IOP for the patient's worse eye at baseline was used in the secondary endpoint analysis. 2 consecutive IOP measurements for each eye were taken. If the 2 measurements for the same eye differ by 4 mmHg or less, the average of the measurements would be considered as the mean IOP for that eye. If the 2 measurements for the same eye differ by more than 4 mmHg, then a third measurement was to be taken. All IOP measurements were performed with a Goldmann applanation tonometer.
Interventions
- DRUG Travatan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 502 participants |
| Start Date | 2006-01 |
| Phase | Phase 3 |
What the finished NCT00051168 record still lists
NCT00051168 is an interventional study that assigns participants to a tested intervention. The registered 502 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 1 intervention - of which Travatan is the first listed.
NCT00051168 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00051168 about?
NCT00051168 is a clinical study titled "A Long-term Safety Study of Once-daily Travatan". Long term safety study of TRAVATAN in patients with Open-angle glaucoma or ocular hypertension.
What is the current status of trial NCT00051168?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 502 participants. The study started on 2006-01.
What interventions are being tested in trial NCT00051168?
The interventions under investigation include: Travatan (DRUG).
Who is sponsoring clinical trial NCT00051168?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00051168's enrollment target sits among peer trials
502 743rd of 2000 higher than 1,258 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05646381 · 502 participants · Phase 2
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
- NCT05897632 · 502 participants · NA
CARE-CP (Testing a Cardiovascular Ambulatory Rapid Evaluation for Patients With Chest Pain)
- NCT05143931 · 503 participants · NA
Avoid and Resist Strategies for Weight Management
- NCT04442022 · 501 participants · Phase 2
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia